Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;125(2):138-143.
doi: 10.1080/03009734.2020.1737599. Epub 2020 Mar 25.

Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention

Juan Carlos Castillo  1 , Thor Haahr  2   3 , María Martínez-Moya  1 , Peter Humaidan  2   3
Affiliations
Review

Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention

Juan Carlos Castillo et al. Ups J Med Sci. 2020 May.

Abstract

In this review the advantages of the gonadotropin-releasing hormone agonist (GnRHa) trigger are discussed beyond those immediately associated with ovarian hyperstimulation syndrome (OHSS) prevention. The GnRHa trigger concept has sparked the development of novel protocols, enriching the assisted reproductive technology (ART) armamentarium for the benefit of present and future patients. Thus, GnRHa trigger already has a pivotal role, not only for the standard in vitro fertilisation (IVF) patient, but also for patient groups like oocyte donors, cancer patients, patients with poor ovarian reserve, and patients with immature oocyte syndrome and empty follicle syndrome. Herein, we discuss the importance of the GnRHa-elicited midcycle FSH surge and the potential improvement in oocyte yield and embryo competence.

Keywords: Cancer; GnRH trigger; IVF; hCG; oocyte donation; ovulation trigger.

PubMed Disclaimer

Conflict of interest statement

Not related to this manuscript, TH received honoraria for lectures from Ferring, IBSA, Besins, and Merck. PH received unrestricted research grants from MSD, Merck, and Ferring as well as honoraria for lectures from MSD, Merck, Gedeon-Richter, Theramex, and IBSA. PH and TH are listed as inventors in an international patent application (PCT/UK2018/040882).

References

    1. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983;57:792–6. - PubMed
    1. Imoedemhe DAG, Sigue AB, Pacpaco ELA, Olazo AB. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril. 1991;55:328–32. - PubMed
    1. Humaidan P, Ejdrup Bredkjaer H, Bungum L, Bungum M, Grøndahl ML, Westergaard L, et al. . GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213–20. - PubMed
    1. Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010;20:783–8. - PMC - PubMed
    1. Kol S, Humaidan P. LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango? Reprod Biomed Online. 2010;21:590–2. - PubMed

MeSH terms

Substances